Immutep Ltd (ASX: IMM) Share Price and News

Dr Howard is an Australian scientist, executive manager, and entrepreneur. He was a pioneer in molecular parasitology and commercialisation of DNA Shuffling. He is an inventor of 9 patents and has over 140 scientific publications. After his PhD in biochemistry from the University of Melbourne, he held positions at several research laboratories, including the National Institutes of Health in the USA where he gained tenure. In industry, Dr Howard worked at Schering Plough's DNAX Research Institute in Palo Alto, CA; was the President and Scientific Director of Affymax, Inc. and co-founder and CEO of Maxygen, Inc.

Ms Anderson has board and leadership experience serving Australian and international companies. Anne currently serves as NED of leading Australian wealth manager, BTFM and was previously on the Board of an unlisted subsidiary of Ingenia Communities Group. She currently holds a portfolio of advisory and committee roles including as a Member of the Advisory Board to The Treasury (Australia), Member of the EnergyCo Transmission Acceleration Facility Investment Committee for the NSW Treasury, Advisor to the REST Board Investment Committee, Independent Member of the Minderoo Foundation and E&P Financial Group Investment Committees and Member of the ASIC Consultative Panel. Prior to her NED and committee roles, she completed an executive career of more than 35 years spanning the energy and global financial services sectors.

Mr Meyers is the Chief Financial Officer of Slayback Pharma LLC. Prior to joining Slayback, Mr Meyers served in Chief Financial Officer roles at Eagle Pharmaceuticals, Inc., Motif BioSciences Inc. and TetraLogic Pharmaceuticals Corporation. Prior to his role at TetraLogic, Mr Meyers spent 18 years in health care investment banking, holding positions of increasing responsibility at Dillon, Read &Co., Credit Suisse First Boston LLC.

Mr Voigt has more than 21 years of experience in the financial and biotech industry, having joined the Immutep team in 2011 as the General Manager, European Operations based in Berlin, Germany. In May 2012, he became Immutep 's Chief Business Officer and in November 2012 its Chief Financial Officer, as well as continuing to focus on its European operations. Having started his career at the Allianz Group working in pension insurances and funds, he moved to net.IPO AG, a publicly listed boutique investment bank in Frankfurt where he was focused on IPOs and venture capital investments.

Professor Triebel founded Immutep S.A. in 2001 to develop LAG-3 product candidates as human medicines and became Chief Medical Officer and Chief Scientific Officer of Immutep following the Company's acquisition of Immutep S.A in December 2014. While working at IGR as an oncologist, he was also a Professor in Immunology at Paris University and a Director of an INSERM Unit from 1991 to 1996.

Ms Boyce is corporate lawyer. She is currently a partner at Piper Alderman and was previously a partner at Dentons, having been at DibbsBarker for nearly 30 years. She has involvement in the Life Sciences and Healthcare sectors and is currently deputy chair of AusBiotechs AusMedtech Advisory Group and a member of AusBiotechs NSW Leadership Committee.

-

-

-

-